Dilated Cardiomyopathy - Pipeline Insight, 2024

This Dilated Cardiomyopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dilated Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dilated Cardiomyopathy Understanding

Dilated Cardiomyopathy: Overview

Dilated Cardiomyopathy (DCM) is a disease of the heart muscle characterized by enlargement and dilation of one or both of the ventricles along with impaired contractility defined as left ventricular ejection fraction (LVEF) less than 40%. In most cases DCM is progressive, leading to heart failure and death. Without a transplant, the survival rates are poor.

DCM has many causes and all of them affect the ventricular function to a varying degree. While most patients with DCM have symptoms, a few patients may be asymptomatic because of the compensatory mechanisms. The continued enlargement fo the ventricles leads to a decline in ventricular function, followed by conduction system abnormalities, ventricular arrhythmias, thromboembolism, and heart failure. The earlier these patients are identified and treated, the better the prognosis.

Dilated Cardiomyopathy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dilated Cardiomyopathy pipeline landscape is provided which includes the disease overview and Dilated Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Dilated Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dilated Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Dilated Cardiomyopathy. The therapies under development are focused on novel approaches to treat/improve Dilated Cardiomyopathy.

Dilated Cardiomyopathy Emerging Drugs

Danicamtiv: MyoKardia
Danicamtiv (formerly MYK-491) is an oral, small molecule, selective cardiac myosin activator. In the heart, myosin is the motor protein that binds to actin to generate the force and movement of contraction. In patients with dilated cardiomyopathy and systolic heart failure, the left ventricle of the heart is too distended and weak to adequately pump blood to meet the body’s needs. Danicamtiv has been shown to increase the probability for myosin-actin engagement while preserving the detachment of myosin from actin at the end of contraction, thereby improving cardiac contractility while preserving diastolic function and allowing for normal filling.

Ixmyelocel-T: Vericel
Ixmyelocel-T is an investigational autologous expanded multicellular therapy manufactured from the patient's own bone marrow using Vericel's proprietary, highly automated, fully closed cell-processing system. This process selectively expands the population of mesenchymal stromal cells and alternatively activated macrophages, which are responsible for production of anti-inflammatory and pro-angiogenic factors known to be important for repair of damaged tissue. Ixmyelocel-T has been designated as an orphan drug by the US Food and Drug Administration for use in the treatment of DCM.

Dilated Cardiomyopathy: Therapeutic Assessment

This segment of the report provides insights about the Dilated Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dilated Cardiomyopathy

There are approx. 10+ key companies which are developing the therapies Dilated Cardiomyopathy. The companies which have their Dilated Cardiomyopathy drug candidates in the most advanced stage, i.e phase III include Pfizer

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dilated Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dilated Cardiomyopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dilated Cardiomyopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dilated Cardiomyopathy drugs.

Dilated Cardiomyopathy Report Insights

• Dilated Cardiomyopathy Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dilated Cardiomyopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dilated Cardiomyopathy drugs?
• How many Dilated Cardiomyopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dilated Cardiomyopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dilated Cardiomyopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dilated Cardiomyopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Renovacor
• Pfizer
• Longeveron
• MyoKardia
• Berlin Cures
• Vericel
• Tenaya Therapeutics
• Cardior Pharmaceuticals
• Help Therapeutics

Key Products

• REN 001
• Emprumapimod
• Mesenchymal stem cell therapy
• Danicamtiv
• BC 007
• Ixmyelocel-T
• TN 301
• CDR 426D
• hiPSC-CM therapy

This product will be delivered within 1-3 business days.